1. Home
  2. RGNX vs BACQ Comparison

RGNX vs BACQ Comparison

Compare RGNX & BACQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGNX
  • BACQ
  • Stock Information
  • Founded
  • RGNX 2008
  • BACQ 2024
  • Country
  • RGNX United States
  • BACQ United States
  • Employees
  • RGNX N/A
  • BACQ N/A
  • Industry
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • BACQ
  • Sector
  • RGNX Health Care
  • BACQ
  • Exchange
  • RGNX Nasdaq
  • BACQ NYSE
  • Market Cap
  • RGNX 387.0M
  • BACQ 333.2M
  • IPO Year
  • RGNX 2015
  • BACQ 2024
  • Fundamental
  • Price
  • RGNX $8.85
  • BACQ $10.24
  • Analyst Decision
  • RGNX Strong Buy
  • BACQ
  • Analyst Count
  • RGNX 8
  • BACQ 0
  • Target Price
  • RGNX $31.75
  • BACQ N/A
  • AVG Volume (30 Days)
  • RGNX 1.3M
  • BACQ 53.6K
  • Earning Date
  • RGNX 05-12-2025
  • BACQ 01-01-0001
  • Dividend Yield
  • RGNX N/A
  • BACQ N/A
  • EPS Growth
  • RGNX N/A
  • BACQ N/A
  • EPS
  • RGNX N/A
  • BACQ N/A
  • Revenue
  • RGNX $156,718,000.00
  • BACQ N/A
  • Revenue This Year
  • RGNX $313.52
  • BACQ N/A
  • Revenue Next Year
  • RGNX N/A
  • BACQ N/A
  • P/E Ratio
  • RGNX N/A
  • BACQ $113.74
  • Revenue Growth
  • RGNX 80.70
  • BACQ N/A
  • 52 Week Low
  • RGNX $5.04
  • BACQ $9.80
  • 52 Week High
  • RGNX $15.36
  • BACQ $10.24
  • Technical
  • Relative Strength Index (RSI)
  • RGNX 51.64
  • BACQ N/A
  • Support Level
  • RGNX $7.68
  • BACQ N/A
  • Resistance Level
  • RGNX $9.29
  • BACQ N/A
  • Average True Range (ATR)
  • RGNX 0.85
  • BACQ 0.00
  • MACD
  • RGNX -0.08
  • BACQ 0.00
  • Stochastic Oscillator
  • RGNX 43.42
  • BACQ 0.00

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

About BACQ BLEICHROEDER ACQUISITION CORP. I

Bleichroeder Acquisition Corp I is a blank check company.

Share on Social Networks: